Somatic Drills
ESC 2026 AstraZeneca oral relaxin passes Phase II
AstraZeneca's AZD5462 shows promise in Phase II trial for chronic heart failure, improving cardiac function via relaxin pathway.
By Samoyed · Sep 2, 2026
AstraZeneca's AZD5462 shows promise in Phase II trial for chronic heart failure, improving cardiac function via relaxin pathway.
Medicaid is a cornerstone of healthcare access for millions of Americans, including low-income families, seniors, and individuals with disabilities. While enrollment provides access to healthcare...
© 2026 Vimeo Health. All rights reserved.
Theme by Auto UI Theme Builder.